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Generation of an immortalised 
erythroid cell line 
from haematopoietic stem cells 
of a haemoglobin e/β‑thalassemia 
patient
Kongtana trakarnsanga1*, chartsiam tipgomut1, chanatip Metheetrairut1, 
Methichit Wattanapanitch2, Archrob Khuhapinant3, Saiphon poldee1, Ryo Kurita4, 
Yukio nakamura5, chatchawan Srisawat1 & Jan frayne6,7*
The β-thalassemia syndromes are the most prevalent genetic disorder globally, characterised by 
reduced or absent β-globin chain synthesis. HbE/β-thalassemia is a subtype of β-thalassemia with 
extremely high frequency in Asia. Studying molecular defects behind β-thalassemia is severely 
impeded by paucity of material from patients and lack of suitable cell lines. Approaches to derive 
erythroid cells from induced pluripotent stem cells (ipScs) created from patients are confounded 
by poor levels of erythroid cell expansion, aberrant or incomplete erythroid differentiation and 
foetal/embryonic rather than adult globin expression. In this study we generate an immortalised 
erythroid cell line from peripheral blood stem cells of a HbE/β-thalassemia patient. Morphological 
analysis shows the cells are proerythroblasts with some early basophilic erythroblasts, with no 
change in morphology over time in culture. The line differentiates along the erythroid pathway 
to orthochromatic erythroblasts and reticulocytes. Importantly, unlike iPSCs, the line maintains 
the haemoglobin profile of the patient’s red blood cells. This is the first human cellular model 
for β-thalassemia providing a sustainable source of disease cells for studying underlying disease 
mechanisms and for use as drug screening platform, particularly for reagents designed to increase 
foetal haemoglobin expression as we have additionally demonstrated with hydroxyurea.
β-thalassemia is a common genetic disorder with high prevalence in areas where malaria is (or was) highly 
endemic. It can be caused by any of over 300 mutations in and around the β-globin gene, resulting in reduced 
or absent β-globin synthesis, a component of haemoglobin (Hb) in red blood cells (RBCs) required for oxygen 
delivery in the body. A particular subtype, HbE/β-thalassemia, with extremely high frequency in many countries 
in  Asia1, is caused by compound heterozygous mutation of the β-globin genes. Mutation of the one allele causes 
reduction or absence of β-globin production (dependent on the mutation present), whilst the HbE mutation 
causes aberrant splicing of a proportion of transcripts along with a structural variant of the β-globin translated 
from the remaining normally spliced transcripts, with overall reduced levels of protein produced. In all cases of 
β-thalassemia reduced or absent expression of β-globin results in globin chain imbalance with excess α-globin 
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forming insoluble aggregates which undergo auto-oxidation leading to increased ROS and a range of intracellular 
downstream events resulting in the observed disease  pathophysiology2.
At present, treatment for most thalassemia patients is regular blood transfusions, with resultant consequences 
such as iron overload and transfusion reactions. Bone marrow transplant, a curative treatment, is limited to 
patients who have compatible stem cell donors, and is not an accessible therapy for many patients in low and 
middle-income countries where the disease is prevalent. Clinical advances have been achieved using autolo-
gous transplantation and β-globin gene transfer (reviewed by Dreuzy et al.3). However, such gene therapy is 
still largely experimental and expensive, with efficacy and safety issues being of major concerns (reviewed by 
Cappellini et al.2).
Individuals with concomitant hereditary persistence of foetal haemoglobin and β-thalassemia exhibit reduced 
disease  severity4, due to reduction in the concentration of free α-globin subunits. Hence increasing the level of 
foetal haemoglobin (HbF) in patients has the potential to ameliorate clinical symptoms, and is a major focus of 
much ongoing research (reviewed by Cappellini et al.2). However, currently, much of the knowledge of erythro-
poiesis and red blood cell disorders, such as β-thalassemia is based on mouse  models5–7. Although these studies 
are valuable, fundamental differences between mouse and human erythropoiesis are becoming more  apparent8–10.
Erythroid cells can be differentiated in vitro from peripheral blood stem cells. However, the cells have a 
limited capacity for self-renewal with the total number of erythroid cells produced restricted by their expan-
sion  potential11. In order to generate sufficient quantities of cells for study, repeated collections of stem cells are 
therefore required, an inappropriate approach if requiring cells from anaemic patients. Thus, new approaches 
for studying β-thalassemia are essential for understanding the underlying molecular mechanisms, developing 
new therapeutics and creating screening platforms for the development of new drugs.
A number of reports have derived iPSCs from thalassemic  patients12,13, however erythroid cells differentiated 
from iPSCs are confounded by poor levels of expansion, aberrant or incomplete erythroid differentiation and 
express predominantly foetal/embryonic rather than adult  globin14, 15 making them unsuitable as model lines. 
We previously developed methodology and generated an adult human immortalised erythroid cell line (BEL-
A) that recapitulates normal erythropoiesis, expresses normal levels of adult globin, terminally differentiates 
and enucleates to generate mature  reticulocytes16. We have now taken this approach forward, creating the first 
immortalised line from a patient with HbE/β-thalassemia (Siriraj Bristol Beta-thalassemia/haemoglobin E cell 
line; SiBBE) providing a sustainable supply of cells as a disease model system.
Results and discussion
Generation of an immortalised HbE/β-thalassemia erythroid line (SiBBE). Isolated patient 
 CD34+ cells were transferred to primary medium of our erythroid culture  system17 for 24 h, then transduced 
with a Tet-inducible HPV-E6/E7  construct18. On day 6 the cells were transferred to and maintained in expan-
sion medium as described in Trakarnsanga et al.16, with cell counts and total medium changes every 2–3 days 
(schematic of protocol shown in Fig. 1A). The cell line was maintained in continuous culture for over 100 days, 
with a mean doubling time of 17 h. This is comparable to 18.7 ± 2.0 h for the normal erythroid cell line BEL-A19. 
After 100 days the line was well established with aliquots frozen for storage. Their ability to re-establish on thaw-
ing was confirmed. Morphological analysis showed the cells to be proerythroblasts with some early basophilic 
erythroblasts (Fig. 1B, undif., line age day 114). For further erythroid differentiation and maturation, the cells 
were transferred to primary medium of our erythroid culture  system17 for 6 days, with doxycycline for day 1–4, 
followed by tertiary medium of the same system thereafter. Cells differentiated along the erythroid pathway with 
an enucleation rate of 10.8 ± 0.6% on day 10 (Fig. 1B,C; n = 3). Maximum fold expansion of 8.7 ± 0.4 fold was 
obtained on day 6 of differentiation (Fig. 1C; value calculated from number of cells transferred to differentia-
tion medium). The number and viability of differentiated SiBBE cells decreased after day 6 of differentiation 
(Fig. 1C,D), the timing of cell death corresponding with the majority of the cells being polychromatic erythro-
blasts (Fig. 1C). This is in line with that observed for erythroid cells differentiated from β-thalassemia patient 
 CD34+ cells which apoptose at the polychromatic stage due to ineffective  erythropoiesis20,21. In contrast the 
normal erythroid cell line BEL-A cells decrease in number after day 8 due to death of orthochromatic erythro-
blasts that fail to  enucleate19. The expression of HPV16 E6 and E7 was lost from the cells following removal of 
doxycycline on day 4 of differentiation (Fig. 1E).
Figure 1.  (A) A schematic diagram illustrating steps in the generation of the immortalised erythroid cell 
line (SiBBE) from stem cells collected from blood of a patient with haemoglobin E/β-thalassemia. (B) 
Undifferentiated erythroid cells (undif.) on day 114 in expansion medium and differentiated erythroid 
cells (dif.) on day 2, 4, 6, 8 and 10 in erythroid differentiation medium stained with Leishman reagent and 
analysed by light microscopy (scale bar = 10 μm). Green arrows = proerythroblasts; Blue arrows = basophilic 
erythroblasts; Orange arrows = polychromatic erythroblasts; black arrows = orthochromatic erythroblasts; red 
arrows = reticulocytes. (C) Extrapolated number of erythroid cell types at different time points during erythroid 
differentiation (mean ± SD, n = 3). (D) Percentage of living cells during erythroid differentiation determined 
by Trypan blue assay (mean ± SD, n = 3). (E) Expression of HPV16 E6, E7 and gamma globin (HBG) (control) 
determined by RT-PCR. Full-length gels are presented in Supplementary Fig. 3. (F) Undifferentiated early (day 
81) and late (day 144) passage cells in expansion medium (undif.) and at day 10 in differentiation medium 
(dif. day 10) stained with Leishman reagent and analysed by light microscopy (scale bar = 10 μm). (G) Flow 
cytometric analysis of cells in (E) incubated with antibodies to glycophorin A (GPA; CD235a) and CD36. (H) 
Extrapolated cell numbers of early (day 77 to 81; blue) and late (day 136 to 144; orange) passage cells during 
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There was no change in morphology of the cells over time in culture (Fig. 1F, day 81 and 144, undif.). This 
was confirmed by flow cytometry analysis of CD36 and glycophorin  A22 levels for cells at line age day 77 to 
81 and day 136 to 144 (Fig. 1G top panels, representative populations of early and late SiBBE passage shown). 
95.4 ± 0.9% undifferentiated early cells were  GPAmed/highCD36high compared to 93 ± 2.6% for the late population 
(p > 0.05; n = 3).
To confirm unchanged differentiation of SiBBE after prolonged expansion, early and late passage cells (as 
above) were transferred to differentiation medium. There was no significant difference in expansion kinetics 
of the early and late SiBBE cells during differentiation (Fig. 1H). At the end of differentiation (day 10), the 
early passage population was 17.4 ± 1.6% polychromatic erythroblasts, 72.6 ± 1.7% orthochromatic erythroblasts 
and 10.0 ± 1.1% reticulocytes, and the late passage population was 17.6 ± 1.4% polychromatic erythroblasts, 
72.0 ± 1.6% orthochromatic erythroblasts and 10.4 ± 0.6% reticulocytes (p > 0.05; n = 3) (Fig. 1F, dif. day 10; 
representative images of cell morphology shown). Flow cytometry analysis of the differentiated cells on day 10 
showed no significant difference between the levels of GPA and CD36 between the early and late passage popula-
tions, 86.7 ± 2.9% and 81.2 ± 3.1% of differentiated early and late populations were  GPAhighCD36low, respectively 
(p > 0.05; n = 3) (Fig. 1G, lower panels; representative flow plots shown). There was also no significant difference 
in enucleation rates, 10.0 ± 1.1% in the differentiated early cells compared to 10.4 ± 0.6% in the differentiated late 
cells (p > 0.05, n = 3). These data confirm no difference in behaviour or phenotype of SiBBE following prolonged 
expansion.
Similar to other immortalised erythroid cell  lines19, SiBBE is a mixed clonal population, revealing a modal 
chromosome number of 49, XX range 48–50 (50 metaphases). The most common variation were trisomies of 
chromosome 6, 15 and 19 (34 out of 50), while the rest were other chromosome anomalies including transloca-
tions, partial deletions, pseudodicentric and derivative chromosomes (shown in Supplementary Table 1 and 
Supplementary Fig. 1).
Further characterisation of SiBBE during differentiation. Flow cytometric analysis was performed 
with antibodies to key RBC membrane proteins. The undifferentiated cell line (day 77) expressed erythroid 
markers GPA, CD36, α4-integrin, Rh and RhAG (Fig. 2A, day 0). 41.2 ± 2.4% (n = 3) of cells expressed Band3, 
which represent the basophilic erythroblast proportion in the population. Following transfer to differentiation 
media, the level of GPA and Band3 increased whilst the level of CD36 and α4-integrin decreased (Fig. 2A, upper 
panel) as  expected22. The level of Rh and RhAG was maintained. To more accurately assess differentiation, the 
inverse expression of Band 3 vs α4-integrin19,22 and GPA vs  CD3619 was analyzed using dual staining. More 
than 95% of undifferentiated SiBBE (day 0) expressed  GPAmedCD36high and  Band3low/medα4-integrinhigh, similar 
to the profiles of cultured primary pro-/basophilic erythroblasts and the undifferentiated BEL-A  line19,22. Fol-
lowing transfer to differentiation medium, the expression of GPA and Band3 was inversely related to that of 
CD36 and α4 integrin, respectively (Fig. 2A, lower panel). At the end of differentiation (day 10), approximately 
56.1 ± 9.1% (n = 3) of remaining cells were  Band3high α4-integrinlow, with the remainder having slightly higher 
levels of α4-integrin, a profile expected for a population of predominately orthochromatic  erythroblasts19,22, and 
in line with the morphological analysis (Fig. 1B).
Globin profile of SiBBE. Before differentiation, the centrifuged SiBBE cells produced pink cell pellets, 
whereas after differentiation, cells produced red pellets (Fig. 2B), indicating haemoglobin synthesis. Importantly, 
HPLC analysis showed the differentiated cells expressed a closely similar globin profile to that of the patient 
RBCs (Fig. 2C). Total Hb level of the patient blood was 5.5 g.dl−1 (normal range 12.5–16.8 g.dl−1) of which the 
globin subunit proportions were 24.4% HbF, 5.9% HbA and 69.7% HbE, compared to 29.2% HbF, 9.0% HbA 
and 61.8% HbE in SiBBE cells. Hence, unlike erythroid cells differentiated from iPSCs of thalassemic  patients12 
the cells maintain expression of adult globin subunits. The line thus presents as an ideal model for evaluating 
reagents that reactivate foetal globin expression, increasing and normalising total haemaglobin levels whilst in 
a thalassemic background.
Increased foetal globin on treatment of SiBBE with hydroxyurea. To demonstrate the potential 
of the line as such a screening platform, the cells were treated with hydroxyurea (HU), a drug approved by FDA 
as a foetal haemoglobin inducer for sickle cell anaemia patients (reviewed by Pule et al.23). 25 μM HU were 
added to the expansion medium for 4 days, and maintained at the same concentration throughout differentia-
tion. There were slightly fewer cells detected in HU treated cultures, but this only reached significance on day 8 
of culture (p < 0.05) (Fig. 3A) and may be due to the slightly accelerated differentiation of the HU treated cells; 
association between reduced proliferation and expedited differentiation of erythroid cells is well  documented24. 
Figure 3B shows the inverse expression of CD36 vs GPA and α4-integrin vs Band3, whereby there were more 
 GPAhighCD36low (12.7% for HU vs 7.6% for control) and  Band3high α4-integrinlow (37% for HU vs 2.5% for con-
trol) cells in the HU treated culture at day 6 than in the untreated control culture. Viability of the cells was 
unaffected by HU treatment (Fig. 3C). By day 10, HU treated and control cells were at a comparable stage of 
differentiation and were harvested to determine globin levels by immunoblot. HU treated cells expressed sig-
nificantly higher γ-globin than controls (Fig. 3D). There was no corresponding decrease in β-globin levels after 
HU treatment (Fig. 3D), similar to that found in a previous  study19, likely due to the long half-life and thus 
persistence of β-globin in cells.
In conclusion, we have generated a model disease erythroid cell line via immortalisation of early erythroid 
cells differentiated from peripheral blood stem cells of a patient with HbE/β-thalassemia. The cell line recapitu-
lates the globin profile of the patient’s erythroid cells, exhibits a level of ineffective erythropoiesis as found in 
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Figure 2.  (A) Flow cytometric analysis of SiBBE on day 77 in expansion medium showing key erythroid 
cell marker levels in undifferentiated cells (day 0) and differentiated cells on day 3, 5, 7 and 10 in erythroid 
differentiation medium. Cells were incubated with antibodies to CD36, glycophorin A, α4 integrin, band3, Rh 
and RhAG followed by incubation with an IgG1 APC secondary antibody, or with α4 integrin FITC conjugate. 
The cells were also dual stained by incubation with antibodies to CD36 and GPA or α4 integrin and band 3. (B) 
Pellets of undifferentiated erythroid cells and differentiated erythroid cells on day 8 in culture. (C) HPLC traces 
showing HbF, HbA and HbE levels in the patient RBC and the differentiated cell line (SiBBE).
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Figure 3.  (A) Extrapolated cell numbers of HU treated erythroid cells (blue) and control cells (green) 
(mean ± SD, n = 3). (B) Flow cytometric analysis of the cell line showing erythroid differentiation of HU treated 
erythroid cells and control cells. The cells were dual stained with anti-CD36 or anti-α4 integrin and anti-GPA 
or anti-band 3. (C) Percentage of living cells of HU treated erythroid cells (blue) and control cells (green) 
determined by Trypan blue assay (mean ± SD, n = 3). (D) Gamma and beta globin expression in HU treated 
erythroid cells (blue) and control cells (green) analysed by Western blot analysis. Alpha globin was used as 
control. Western blot is representative of 3 repeats. Density of bands on Western blots were quantified using 
ImageJ (mean ± SD, p < 0.05 by T-test, n = 3). Full-length blots are presented in Supplementary Fig. 4.
7
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16798  | https://doi.org/10.1038/s41598-020-73991-4
www.nature.com/scientificreports/
β-thalassemia20,21 and can be induced to increase expression of foetal globin, thus providing a sustainable supply 
of disease cells for studying pathophysiology of the disease and as a screening platform for novel treatments.
The line has a number of advantages over other models,  CD34+ cells and iPSCs from β-thalassemia patients, 
for erythroid culture. Although erythroid cells differentiated in vitro from peripheral blood  CD34+ cells have a 
higher expansion rate during differentiation compared to SiBBE using a similar culture  system17, they undergo a 
restricted number of cell divisions before terminally differentiating and enucleating, necessitating repeat collec-
tion of  CD34+ cells for repeat cultures. In contrast the unrestricted expansion potential of undifferentiated SiBBE 
permits a resultant ‘yield’ of differentiated erythroid cells restricted only by volume feasibility and culture cost. 
This sustainable supply of disease cells also avoids variability introduced due to heterogeneity between patients. 
The expansion rate of SiBBE during differentiation is in line with that of our immortalised normal erythroid cell 
lines (BEL-A19 and additional lines; paper in preparation). iPSC lines created from β-thalassemia patient cells 
have the potential to provide a sustainable source of cells, with the reported expansion potential of differentiated 
erythroid cells from normal iPSC higher than SiBBE but varying widely (33 to 800  fold25–27). However, the cells 
exhibit aberrant or incomplete erythroid differentiation and express predominantly foetal/embryonic rather than 
adult  globin12,14,15 making them unsuitable for model lines. Furthermore, iPSC requires complex haematopoietic 
differentiation systems to obtain haematopoietic stem cells which further limits their practicality; SiBBE already 
being at an early erythroid cell stage.
Materials and methods
Cell isolation and culture. The study was performed in accordance with the Declaration of Helsinki 
and after approval by the local research ethics committees (The Siriraj Institutional Review Board, SIRB; COA 
no. SI159/2018). Written informed consent was obtained from a donor who had been diagnosed as HbE/β-
thalassemia (HBB: c.9T>C Het, c.79G>A Het (HbE), c.315+16G>C Het, c.316-185C>T Hom; Supplementary 
Fig. 2). Peripheral blood  CD34+ cells were isolated from a transfusion dependent HbE/β-thalassemia patient 
at Siriraj Hospital, Bangkok. Thirty millilitres of blood was diluted with equal volume of Hanks’ Balanced Salt 
Solution (HBSS) containing 0.6% (v/v) citrate dextrose solution and separated on a Ficoll-Histopaque density 
gradient at 400g for 30 min at 20 °C. The mononuclear cells were harvested and  CD34+ cells isolated using a 
MiniMacs direct  CD34+ progenitor cell isolation kit (Miltenyi Biotec) following the manufacturer’s instruc-
tions. The  CD34+ cells were then immortalised and cultured as described  previously16,17. Briefly, the isolated 
cells were maintained in primary medium, which was Basic medium (Iscove’s medium (Biochrom) contain-
ing 3% (v/v) human AB serum (Sigma-Aldrich), 2% fetal calf serum (Hyclone, Fisher Scientific), 3 U/ml EPO 
(Roche), 200 μg/ml transferrin (R&D Systems) and 1 U/ml penicillin/streptomycin (Sigma-Aldrich)) supple-
mented with 10 ng/ml SCF (R&D Systems) and 1 ng/ml IL-3 (R&D Systems), for 24 h and then transduced with 
a Tet-inducible HPV-E6/E7 construct. On day 6, the cells were transferred to expansion medium, which was 
Stemspan SFEM (STEMCELL Technologies) supplemented with 3 U/ml EPO,  10–6 M dexamethasone (Sigma-
Aldrich), 50 ng/ml SCF and 1 μg/ml doxycycline (Takara Bio), and maintained in this medium thereafter. The 
cells were counted using trypan blue staining and maintained at density of 2–5 × 105/ml at 37 °C, 5%  CO2 with 
total medium changes performed every 2–3 days.
To induce erythroid differentiation, the cultured cells were transferred to primary medium and maintained for 
6 days (doxycycline was included from day 0 to day 4). After day 6, the cells were transferred to and maintained in 
tertiary medium which was Basic medium supplemented with 500 μg/ml transferrin. The cells were counted using 
trypan blue staining and maintained at 37 °C, 5%  CO2 with total medium changes performed every other day.
PCR analysis. 400 ng of RNA was reverse transcribed into cDNA using SuperScript III reverse transcriptase 
(Invitrogen). Primers (Sigma-Aldrich) used were HPV16 E6 fwd GCG ACC CAG AAA GTT ACC AC rev GCA 
ACA AGA CAT ACA TCG ACCGG; HPV16 E7 fwd GCA ACC AGA GAC AAC TGA TCTC rev TGG GGC ACA CAA 
TTC CTA GTG; Gamma globin fwd TGG GTC ATT TCA CAG AGG AG rev AGA CAA CCA GGA GCC TTC C.
Flow cytometry. Aliquots of 2 × 105 cells were washed with 500 μL PBS containing 2  mg.ml−1 glucose 
and 1% BSA (PBS-AG). The cell pellet was resuspended in 50 μL of respective primary antibodies (anti-CD36, 
anti-α4 integrin FITC conjugates, both from Miltenyi Biotec, anti-CD235a [BRIC256], anti-CD233 [BRIC71], 
anti-Rh [BRIC69] and anti-RhAG [LA1818] all from IBGRL, Bristol, UK) and incubated for 60 min at 4 °C. The 
cells were centrifuged at 400g and washed once with 500 μL PBS-AG. The cell pellet was resuspended in 50 μL 
anti-mouse IgG1 APC secondary antibody (Biolegend) and incubated for 30 min at 4 °C, followed by washing as 
above. For dual staining cells were co-stained with 50 μL of fluorescent-conjugated antibodies and incubated for 
30 min at 4 °C, centrifuged at 400g and resuspended in 300 μL PBS-AG for analysis on a FACSCalibur (Becton 
Dickinson).
SDS-PAGE and Western blot. Proteins were resolved by SDS-PAGE and transferred to PVDF membranes 
(Millipore) by Western blot. Membranes were blocked with 10% milk powder followed by incubation with pri-
mary antibodies (anti-α globin, anti-β globin, anti-γ globin; all Santa Cruz Biotechnology) at 1:2,000 dilution 
and secondary antibody (rabbit anti-mouse immunoglobulin-HRP; Abcam) at 1:2,000 dilution. Membranes 
were incubated with Immobilon Crescendo Western HRP substrate (Merck) for 5 min and bands visualised 
using Image Quant LAS4000 (GE Lifescience).
Data availability
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